Curex logo.PNG
Curex Revolutionizing Allergy Immunotherapy with Telehealth and Home-Delivered Allergy Drops
28 déc. 2023 18h00 HE | Curex
New York,NY, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Allergy sufferers looking to treat their allergies without the pain and inconvenience of weekly visits to their doctor now have an ally in an at-home...
22157.jpg
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
14 déc. 2023 05h43 HE | Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
22157.jpg
Immuno-Oncology Research Advances: 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Insights
14 déc. 2023 05h38 HE | Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "CCR8-Targeted Antibody Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A novel research publication...
EnGeneIC_Logo.png
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
07 déc. 2023 19h51 HE | EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
22157.jpg
United States Liver Cancer Therapeutics Research Report 2023: Markets, Competition, Forecast and Opportunities, 2018-2028
07 déc. 2023 11h08 HE | Research and Markets
Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
22157.jpg
MesoPher as a Maintenance Treatment after Chemotherapy, 2023 Research Report: Drug Insights and Market Forecasts, 2019-2032 - Focus on 7 Major Markets
23 nov. 2023 11h13 HE | Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "MesoPher Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
22157.jpg
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
22 nov. 2023 08h58 HE | Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
Logo edited.jpg
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
21 nov. 2023 06h00 HE | Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Immatics Final logo (R)_white_background.png
Immatics Announces Third Quarter 2023 Financial Results and Business Update
14 nov. 2023 07h00 HE | https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
Logo.jpg
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
13 nov. 2023 08h30 HE | Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...